Wedbush maintains Outperform rating on ORIC Pharmaceuticals, $14 price target

Wedbush kept an Outperform rating and $14 price target on ORIC Pharmaceuticals, suggesting a 56.3% upside from the last close. The firm cited strong clinical data for ORIC-944 and ORIC-114, with an 88% disease control rate, and the company's strategic focus on cancer therapies.

Original reporting
Published Oct 27, 2026, 1:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wedbush maintains Outperform rating on ORIC Pharmaceuticals, $14 price target — source image
Decision brief

The 30-second read

$ORICBullishMed
01

Why it matters

The analyst's confidence in the pipeline suggests a re‑rating could attract new capital, but the company's small market cap makes the move volatile.

02

Market read

A fresh Outperform rating with a substantial price target increase provides a short‑term catalyst for ORIC shares.

03

What to watch

Potential regulatory hurdles and the need for larger trials could delay commercialization.

Relevance 6/10Novelty 6/10Timing: today

Background

Wedbush's note highlights early clinical data for ORIC-944 and ORIC-114, noting an 88% disease control rate in heavily pretreated patients.

Company-level read

Ticker impact

$ORICBullishMedium confidence
Context

Wedbush upgraded ORIC Pharmaceuticals to Outperform with a new $14 price target, implying 56% upside from the recent close.

Expected impact

potential upside as investors price in the new target

Evidence & confidence

The rating change is a fresh analyst opinion with a concrete target, offering a clear catalyst for short‑term demand.

Market effects

Positive sentiment may lift other biotech firms with similar early‑stage pipelines.

Limited to US biotech sector; no broader regional effect.

Minor, confined to investors tracking small‑cap biotech stocks.

Counterpoint

The upgrade may be premature given the early‑stage data and lack of commercial revenue.

Key entities

  • Wedbush

    Equity research firm providing the rating and price target.

  • ORIC Pharmaceuticals

    Biopharma developing oncology therapies.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo